Achieving its second FDA orphan drug designation with ketamine. Building a proprietary ketamine-based product pipeline for rare and near-rare disorders in pain and inflammation. Seeking to enter Phase 2 clinical trial in 2022. TORONTO, Oct. 13, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company…


Previous articleMYND Diagnostics Inc. Announces Participation in a Monash University (Australia) Proposal for $3 Million Clinical Trial
Next articleThe Therapeutic Effects of Psychedelics: 2A or Not 2A?-Part 2